• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nycomed Amersham Imaging taps CEO

Article

Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and

Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and will succeed Guy Marlow as chief of Nycomed Amersham’s global contrast business. Marlow is retiring later this year.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.